In the present study, we have investigated the effects of IL-4 on the proliferation and differentiation of leukemic and normal human B cell precursors (BCP). We have demonstrated that IL-4 significantly inhibited spontaneous [3H]thymidine ([3H]-TdR) incorporation by leukemic blasts from some B lineage acute lymphoblastic leukemia (BCP-ALL) patients (8 of 14). Furthermore, IL-4 was found to suppress the spontaneous and factor-dependent (IL-7 and IL-3) proliferation of normal BCP (CD10+ surface [s] IgM-cells) isolated from fetal bone marrow. Maximum growth inhibition of either leukemic or normal BCP was reached at low IL-4 concentrations (10 U/ml), and the effect was specifically neutralized by anti-IL-4 antibody. IL-4 was further found to induce the expression of CD20 antigen on BCP-ALL cells from a number of the cases examined (5 of 8), but in contrast to leukemic cells, IL-4 failed to induce CD20 antigen on normal BCP. Finally, IL-4 was found to induce neither the expression of cytoplasmic mu chain, nor the appearance of sIgM+ cells in cultures of normal or leukemic BCP. Our data indicate that IL-4 has the potential to inhibit cell proliferation in leukemic and normal human B lymphopoiesis but is unable to drive the transition from BCP to mature B cells.
Introduction B cells are continuously generated in mammalian bone marrow, as a result ofthe expansion and differentiation ofprimitive hematopoietic cells. As in the other hematopoietic lineages, B cell ontogeny follows an ordered progression, with discrete well-characterized maturation stages (for reviews on B lineage development, see references [1] [2] [3] [4] . Aberrant events in this scheme may lead to the generation and expansion ofmalignant B cell precursors (BCP)' in B lineage acute lymphoblastic leukemia (ALL). Much effort has been devoted to understanding the factors involved in the regulation ofB cell ontogeny and a number ofcytokines have been shown to play a central role in controlling BCP development. Among other cytokines, IL-4 has been shown to display a wide variety ofbiological effects on various cell types. In particular IL-4 plays an important role in the activation, proliferation and differentiation of mature B lymphocytes (5) (6) (7) . A number of studies have addressed the role of IL-4 in murine BCP development. Thus, IL-4 has been described to stimulate the proliferation of pro B cells (i.e., which display germ-line immunoglobulin genes) (8, 9) . During the less primitive stages ofmurine B cell ontogeny, IL-4 has been described to exert either a suppressive ( 10, 11 ) or a potentiating effect on the generation of cytoplasmic (c) sA (pre-B) cells ( 12) . Finally, IL-4 has been reported to induce the appearance of surface (s) IgM+ murine B cells in culture ( 13, 14) . In humans, only limited information is available on the role of IL-4 in early B cell ontogeny. One report has claimed that IL-4 suppresses BCP proliferation and increases the proportion of cA+ and slgM+ cells in cultures of CD24+ fetal bone marrow cells (15) . However, the notion that IL-4 induces the emergence of slgM+ cells has been subsequently challenged ( 16) . Finally, IL-4 has recently been described to inhibit the proliferation of Philadelphia (Ph ')-positive ALL cells ( 17) . In view of these data, we have extended the investigation of the effects of IL-4 on growth and maturation of leukemic and normal human BCP. Here, we describe that IL-4 inhibits cell proliferation in some, but not all, cases of Ph '-negative BCP-ALL and suppresses growth of normal fetal BCP. However, although capable of inducing expression of CD20 antigen in BCP-ALL, IL-4 failed to deliver a maturation signal for the transition to IgM+ leukemic or normal B cells.
Methods

Collection and isolation ofcells
Bone marrow cells were obtained according to institutional guidelines.
Normal BCP. Fetal femurs were obtained after therapeutic or spontaneous abortions between 18 and 24 wk ofpregnancy, and were kindly provided by Prof. J. L. Touraine (Lyon, France). Fetal bone marrow was collected by scraping and flushing the femurs, and was subsequently filtered on nylon wool to remove bone fragments. Mononuclear fractions isolated by Ficoll-Hypaque gradient centrifugation were depleted of adherent cells as previously described ( 18) . Cells bearing CD I0 antigen were subsequently isolated from nonadherent mononuclear fractions by immune "panning" with the ALB-I anti-CD 10 mAb (Immunotech, Marseille, France), using a technique reported in detail elsewhere ( 19) . As LeBien et al. (20) have reported that CDI0 is a pan B marker in fetal bone marrow sIgM + cells were subsequently depleted from the CDIO population by use ofan anti-IgM mAb (Immunotech) and immunomagnetic beads coated with anti-mouse Ig (Dynabeads M450, Dynal, Oslo, Norway).
Purity of the recovered cells was > 98% as indicated by staining with anti-CD1O mAb (see below). Furthermore, all cells expressed B lineage CD 19 antigen but lacked sIgM, indicating that they represented a virtually pure normal BCP population. In some experiments, CD20+ cells were removed from the CD10+ sIgM-population by sorting with a FACstar+ flow cytometer (Becton, Dickinson & Co., Sunnyvale, CA).
Leukemic BCP. Blast-invaded (> 80%) bone marrow samples were obtained by iliac crest aspiration from 14 pediatric patients at initial diagnosis or relapse of Ph'-negative B lineage ALL. Light-density mononuclear cells were isolated by Ficoll-Hypaque (d = 1.077) (Eurobio, Paris, France) gradient centrifugation.
Leukemic blasts were subsequently depleted of contaminants by immunomagnetic bead depletion (see above) of cells reactive with a cocktail of mAbs against T cells (anti-CD2, CD3) (Aster, La Gaude, France); anti-CD4, CD8 (BL4, BL15, Institut Merieux, Lyon, France), mature B cells (anti-K and -X chains, Immunotech), and myeloid cells (anti-CD33 [My9, Coulter Immunology, Hialeah, FL]; anti-CD14 [Immunotech]). In addition, in some experiments, leukemic samples were depleted of CD20+ cells by labeling with BI anti-CD20 mAb (Coulter Immunology) and immunomagnetic beads (see above).
The characteristics ofthe isolated leukemic BCP are summarized in Table I .
Cell cultures
Suspension cultures of leukemic and normal BCP were established in RPMI 1640 medium supplemented with 10% vol/vol heat-inactivated FCS (Flow Laboratories, Irvine, UK) 10 mM Hepes, 2 mM L-glutamine, 5 x 10' M 2-mercaptoethanol, penicillin (100 U/ml), and streptomycin (100 ,ug/ml) (complete medium).
For proliferation assays, leukemic BCP were seeded in 96-well flatbottom microtest tissue culture plates (Falcon Plastics, Oxnard, CA) at 4 X 104 cells/ 100 ,lI, whereas normal BCP were seeded in 96-well round-bottom plates (Nunc, Roskilde, Denmark) at 104 cells/ 100 I d.
Cells were cultured at 37°C and 5% CO2 in complete medium alone or in the presence ofcytokines (see below), and were subsequently pulsed with 1 uCi methyl-thymidine ([3H]TdR) (Commissariat a i'Energie Atomique, Saclay, France, sp act 25 Ci/mmol) for the last 8 h of cul-ture.
[3H]TdR incorporation data were expressed as counts per min-ute±standard deviation (SD) as measured in triplicate culture wells.
In parallel, normal and leukemic BCP were seeded in 24-well culture plates (Flow Laboratories, Inc., McLean, VA) at 4 X I05 cells/ml for cell counts and phenotype analysis.
Human cytokines
Purified recombinant (r) IL-4 was kindly provided by Dr. P. Trotta (Schering-Plough Research, Bloomfield, NJ) (sp act I07 U/mg). Unless otherwise indicated, experiments were performed with 250 U/ml IL-4, as a standard dose found to be saturating in all assays described in the present study. In this respect, a working concentration of250 U/ml IL-4 is routinely reported for in vitro studies. In addition, IL-4 failed to exhibit any toxic effect on unresponsive cells, even when tested at concentrations as high as 104 U/ml (data not shown). Specificity of the IL-4 effects was evaluated in the presence of a neutralizing heat-inactivated (560C) anti-IL-4 rabbit antiserum (21) added concomitantly with IL-4 at a dilution of 1/ 150. A normal heatinactivated rabbit serum was used as control. Purified rIL-3 (kindly provided by Dr. S. Tindall, Schering-Plough Research; specific activity 5 X 10' U/mg) was used at a concentration of 10 ng/ml, previously described to be optimal for the proliferation of hematopoietic progenitor cells (22) . Purified rIL-7, kindly provided by Dr. F. Lee (DNAX, Palo Alto, CA), was used at 20 U/ml (1 U defined as inducing a half-maximal proliferative response of clone K cells, an IL-7-dependent murine BCP cell line [23] ), a concentration previously determined to be optimal for inducing the proliferation of fetal BCP (24) .
Phenotype analysis
Cell-surface phenotyping was performed by standard immunofluorescence with the following mAbs: HPCA-l (anti-CD34), anti-HLA-DR, Leu 14 (anti-CD22), CALLA (anti-CD10), Leu 12 (anti-CDI9), Leu 16 (anti-CD20) (Becton, Dickinson & Co., Mountain View, CA), BAI (anti-CD24) (Boehringer-Mannheim, GmbH, Mannheim, FRG), all revealed by FITC-goat F(ab')2 anti-mouse Ig (Bioart, Meudon, France); or FITC-conjugated IOBla (anti-CD21) (Immunotech), and anti-IgM (Kallestad, Austin, TX). For detection of intracytoplasmic A chain, cell membranes were permeabilized by 0.3% (wt/vol) saponin (Sigma Chemical Co., St. Louis, MO) before LI  83  91  3  89  89  89  71  <1  <1  10  ID   LI  94  96  2  96  96  96  52  <1  <1   II  ID  LI  97  98  1  97  97  97  35  <1  <1  12  R   LI   70  77  3  80  80  80  43  <1  <1  13  ID   LI   86  84  84  ND  ND  80  30  <1  <1  14  ID  LI  95  97  65  93  98  98  95  <1  <1 Abbreviations: ID/R, initial diagnosis/relapse; FAB, French American British cytologic classification. * Percentage positive cells as determined by immunofluorescence on Ficoll-Hypaque isolated mononuclear bone marrow cells. and during labeling. Fluorescence was analyzed with a FACScan flow cytometer. Positive cells were determined by reference to nonspecific staining by control mAbs ofthe same isotype but unrelated specificity.
Statistical analysis
Statistical significance of inhibition of DNA replication was evaluated by comparing the means according to the formula, t= mA -mB/(s2/ nA + s2/nB) 12 
IL-4 U/ml
Results IL-4 inhibits spontaneous DNA replication in some cases of BCP-ALL. BCP-ALL cells, freshly isolated from diagnostic or relapse specimens, consistently displayed spontaneous [3H]-TdR uptake in the absence of exogenously added cytokines, as measured between days 3 and 7 of culture in liquid medium (Table II) . This spontaneous DNA replication was found to be inhibited in a dose-dependent manner by IL-4, with a maximum effect reached at -10 U/ml ( Fig. 1 A) (cells from case 5 presented in Table I ).
We next tested the effects ofIL-4 on the spontaneous proliferation of cells from 14 cases of B lineage ALL described in Table I . IL-4 was found to significantly (t > 2.77, see Methods) inhibit spontaneous DNA replication in 8 out ofthe 14 cases of BCP-ALL tested (Table II) . Notably, however, IL-4-dependent inhibition of [3H]TdR incorporation was found to be of variable magnitude, ranging between 25% and 80% (Table II) . In some ofthe responsive cases, inhibition of DNA replication was paralleled by a decreased cell recovery in the presence of IL-4 (Table II ) (particularly in cases 2 and 12). However, in several cases of BCP-ALL tested, the relationship between the two effects was not evident (such as in cases 11 and 13) . Finally, inhibition of DNA replication was specifically due to IL-4 because it was abrogated by the addition of a neutralizing anti-IL-4 rabbit antibody, whereas normal rabbit serum used as control had no significant effect (Table III) . Of interest, IL-4 failed to inhibit spontaneous [3H]TdR uptake by the CD20+ cases tested (Table II: cases 6, 13, and  14) . However, some CD20 -cases were also refractory (Table  II: IL-4 inhibits the proliferation ofnormal BCP. In that IL-4 was observed to inhibit the growth of leukemic BCP, we investigated whether this cytokine would also affect the proliferation of normal human BCP. Thus, we cultured highly purified fetal bone marrow CD10+ sIgM-cells in the presence of various combinations of IL-7, IL-3, and IL-4. Fig. 2 illustrates that fetal CD0I sIgM-cells spontaneously incorporated low levels of [3H I TdR as measured on day 6 of culture. Exogenously added IL-7 (20 U/ ml) and IL-3 ( 10 ng/ml) were both able to induce a proliferative response ofthe CDI0+ sIgM-cells (stimulation index = 3.4 and 2.2, respectively). The combination of IL-7 (20 U/ml) and IL-3 ( 10 ng/ ml) was found to result in the highest levels of [3H I TdR incorporation (stimulation index = 9.0). Fig. 2 further illustrates that IL-4 (250 U/ml) inhibited spontaneous [3H]TdR uptake by the fetal BCP and strongly reduced the growth response to IL-7 (inhibition 65%), to IL-3 (inhibition 51%), and to the combination of IL-7 + IL-3 (inhibition 75%).
As depicted in Fig. 1 B, IL-4 inhibited the proliferative response of CDI0+ sIgM-cells to the combination of IL-7 and IL-3 in a dose-dependent manner, with a maximum effect reached at -10 U/ml. Furthermore, the IL-4-induced inhibition of [3HITdR uptake by CDI0 sIgM-cells cultured in the presence of IL-7 + IL-3 was associated with reduced cell recovery, which led to a premature exhaustion of viable cells (Fig.  3) . Finally, as illustrated in Table IV , growth-inhibition by IL-4 could be specifically reversed by addition ofa neutralizing anti-IL-4 antibody at the onset of the culture.
Effects ofIL-4 on the phenotype ofBCP-ALL cells. Because inhibition of cell proliferation is often linked to cell differentiation, we investigated whether IL-4 would induce the maturation of leukemic BCP. We observed that IL-4 induced a dosedependent increase in the percentage of cells expressing CD20 antigen, with a maximum (50% CD20 cells) at -10 U/ml IL-4 ( Fig. 4 ) (case 5 cells). Inasmuch as BCP-ALL populations constitutively contain a variable proportion of CD20' cells (Table I) , we systematically depleted CD20 cells before culture, in order to detect de novo expression of the antigen. Thus, we found that IL-4 induced CD20 expression on CD20-depleted cells ( Table V) from five of eight cases presented in Table I . The responsive cases displayed heterogeneity with respect to the overall numbers of CD20 cells appearing in culture (for example: case 11 vs. case 10), (Table V) , although this variability can be attributed in part to differences in overall cell recovery in the presence of (Table II) . As further illustrated in Table V , all cases displaying induction of CD20 (specific increase in numbers of CD20+ cells) (cases 4, 5, 10, 11, and 12) were also susceptible to growth inhibition by IL-4.
A representative experiment demonstrating CD20 induction (case 4 cells), illustrates that -50% ofthe cells cultured in the presence of IL-4 (250 U/ml) expressed CD20 antigen after 72 h (87 X 103 CD20+ cells) ( Fig. 5 C) , whereas spontaneous appearance of CD20 was only observed on a minor proportion (6%) (Fig. 5 B) of the cells cultured in medium alone (10.5 X 103 CD20' cells). The CD20+ cells were CDI0+ ( Fig.5 D) , indicating that they represent the leukemic population that initially expressed this marker.
In contrast to its effect on CD20 antigen, addition of IL-4, whether to CD20-depleted or total BCP-ALL populations, consistently failed to result in the emergence of cU' or sIgM+ ALL cell in all cases examined (n = 11), as illustrated for a representative example (case 4) ( Fig. 5 ). In this context, IL-4 did not permit the expression of sIgM in cases of pre B (cM+) ALL (case 3, and cu+ BCP-ALL lines) (data not shown). Finally, concomittant with a lack of Ig induction, IL-4 did not induce CD21 antigen on the leukemic BCP (not shown).
These results indicate that, in spite of induction of CD20, IL-4 is unable to drive the maturation of leukemic BCP into Ig' cells.
Effects ofIL-4 on thephenotype ofnormal BCP. Because we showed that IL-4 inhibits the proliferation of normal B lineage precursors, we investigated whether IL-4 would induce their maturation. Thus, fetal CDl0+ sIgM-cells were cultured in the presence or absence of IL-4 (250 U/ml), and cell phenotype was subsequently examined. As illustrated in Fig. 6 , a higher proportion of CD20' cells (45%, corresponding to 4.5 X IO' CD20+ cells) were recovered when CDIO sIgMcells were cultured for 5 d in the presence of IL-4 as compared to medium alone (28%)( 1.9 X 10 5CD20 +cells). However, numbers of CD20 + cells recovered in the presence of IL-4 were not significantly increased as compared to input values (4.3 x I05 CD20 + cells at day 0). As also illustrated in Fig. 6 , the intensity of CD20 expression was higher after culture in IL-4, as compared with day 0 cells. These results indicate either IL-4-dependent induction of CD20 on CD20-cells or a selective survival ofday 0 CD20+ cells and hyperexpression ofCD20 in the presence of IL-4. To address this question, CD20cells were sorted from the CDI0O sIgM-population before culture. Data from such an experiment, illustrated in Fig. 7 , demonstrate that, although CD20 spontaneously reappears on a subset of 12 26 60 * Numbers of CD20' cells (X10-3) specifically appearing in cultures of4 x 10 CD20-BCP-ALL cells in the presence of IL-4 (250 U/ml). Cells seeded were . 1% CD20' as determined by sensitivity of FACScan analysis. Accordingly, data from cases 2, 8, and 9 were not considered to represent induction ofCD20' cells. * Percent inhibition was calculated as described in Table II . 16i-byi0iibi DAY 3 IL-4 CD20 cells ( 18 X I03 CD20+ cells recovered), IL-4 does not significantly promote the induction of CD20 antigen expression on normal BCP ( 15 x IO1 CD20+ cells recovered). As previously reported (24, 25) , sIgM' cells emerged in culture of CD 10 + sIgMcells in the absence of exogenous factors. Thus, in a representative experiment, after 5 d of culture of CDl0 sIgM-cells in medium alone, we recovered 0.20 X 106 sIgM' cells ( Fig. 6 ). This figure did not differ significantly from the number of sIgM+ cells recovered in the presence of IL-4 (250 U/ml) (0.21 X 106 cells), although a minor cell subset expressed higher levels of sIgM in the IL-4-supplemented cultures (Fig. 6 ). Ofinterest, spontaneous emergence ofsIgM + cells was considerably inhibited by depletion of CD20' cells before culture, and addition of IL-4 (250 U/ml) to the CDl0I sIgM-CD20cells failed to restore the appearance of sIgM' cells ( Fig. 7 ). Addition of IL-4 (250 U/ml) to CDl0 sIgM-BCP did not significantly affect the number of pre B (cIA+) cells recovered in culture (Fig. 6 ). Finally, we consistently failed to detect the appearance of CD2 1+ cells (Fig. 6 ) or slgD' cells (not shown) in cultures of CD 10+ sIgMcells performed either in the presence or absence of IL-4 (250 U/ml). Together, these data indicate that IL-4 does not signal the transition ofnormal BCP to mature lg-bearing B cells.
Discussion
In the present report, we have studied the effects of ILA on normal and leukenic human BCP. We observed that freshly isolated BCP-ALL cells spontaneously undergo DNA replication in culture, in accordance with other studies (26) (27) (28) . Of interest, IL-4 was found to significantly inhibit this spontaneous DNA replication in 8 of 14 Ph'-negative B lineage ALL specimens tested. The important sample-to-sample variability observed with respect to this effect ofIL-4 is likely to reflect the maturation heterogeneity inherent to ALL. Thus, the size and distribution of this IL-4-responsive population could be quite variable among cases of BCP-ALL. We observed no evident correlation between IL-4-dependent inhibition of [3H]TdR incorporation and cell recovery. In this respect, some cases presented a more important IL-4-dependent decrease in cell numbers than expected to result from inhibition of proliferating cells, suggesting that IL-4 may also negatively affect the survival of cells which do not belong to the subset undergoing spontaneous DNA synthesis. Taken together, our data could imply the existence ofdifferent overlap patterns ofthe IL-4-responsive population and the cell subset undergoing spontaneous DNA replication. We further observed that DNA replication was only inhibited by in CD20-BCP-ALL. However, CD20cells differed widely in their sensitivity to this effect, suggesting that lack ofCD20 expression may be necessary but not sufficient for inhibition of DNA replication by IL-4. In this context, the CD20-BCP subset represents primitive cells (CD34+ cqC) in normal B cell ontogeny (29) but acquisition of CD20 antigen represents an asynchronous event in a number of BCP-ALL (30) , as illustrated by case 3 in our present study (CD20 c-u+). Thus, the maturation heterogeneity of CD20-BCP-ALL cells could explain our observed variability in growth inhibition by IL-4.
Additional studies will be necessary to clarify the issue of BCP subsets and IL-4 responsiveness, particularly in relation to the expression of IL-4 receptors. In this respect, some murine BCP lines have been described among the rare cell types lacking detectable IL-4 receptors ( 31 ) .
Our present results extend recent observations by Okabe et al. ( 17) , who described IL-4-dependent inhibition ofgrowth in the majority of Ph'-positive BCP-ALL tested. However, in contrast to our study, these authors did not demonstrate a similar effect in Ph '-negative ALL. This apparent discrepancy may be attributed to the fact that few examples of Ph '-negative leukemias were evaluated in the study of Okabe et al. (only a single case of fresh BCP-ALL).
We recently established that highly purified CD10+ sIgM BCP from normal fetal bone marrow undergo DNA replication in response to IL-7 and IL-3, and that the proliferative response is enhanced by the combination of both factors (24) . Here BCP. Interestingly, IL-4 inhibited both spontaneous and growth factor (IL-3, IL-7 )-induced DNA replication. This indicates that IL-4 acts as a general negative growth regulator in B cell development rather than as a specific antagonist ofa given growth factor. This contrasts with findings on mature B cells where IL-4 acts as an antagonist ofIL-2 action likely as a consequence of downregulation of IL-2R expression (32, 33) . Our present data confirm and extend the results of Hofman et al.
, who presented evidence for growth-inhibitory effects of IL-4 presumably borne by normal human BCP. It will be of interest to investigate the significance of our inability to detect a growth-stimulatory effect of IL-4 on normal human BCP, as IL-4 has been shown to promote the growth of mouse pro B cells (8, 9) . These differences may reflect that IL-4-dependent proliferation of an early BCP subset would not be detected in our assay owing to growth inhibition of less primitive cells which are present at higher frequency.
Our data indicate that IL-4 promotes a selective survival of CD20 normal BCP which include the most mature precursors. This finding could be related to the lack of growth inhibition observed in CD20 BCP-ALL. It remains to be determined, however, if the normal CD20 subset (which includes DAY4 medium spontaneously emerging sIgM+ cells) contains cells that proliferate in response to IL-4.
In the present study, we further showed that IL-4 induces the appearance ofCD20 antigen on leukemic BCP. We demonstrated that this effect represents de novo expression of CD20, because it could not be accounted for by the expansion of a marginal CD20 subset initially present within the leukemic population. Induction of CD20 expression in response to IL-4 was, however, not a general feature of all BCP-ALL cases tested. As discussed above, this is likely related to the notion that CD20-BCP-ALL cells cover a potentially broad maturation range. Our data suggest that lack of CD20 expression is only one ofthe parameters that determine the influence of IL-4 on BCP-ALL maturation. In this context, it appears of interest that spontaneous DNA replication was inhibited by IL-4 in all cases where CD20 was induced, suggesting that the populations responsive in these two assays overlap or are closely related.
In contrast to BCP-ALL cells, IL-4 failed to induce CD20 expression in normal BCP. These data would suggest that the CD20 gene may be regulated through different mechanisms in normal and leukemic cells. The CD20 surface molecule functions as a channel regulating the entry of Ca"+ into the cell (34) . It remains to be determined how acquisition ofthis function is related to leukemic B cell development.
We further addressed whether the effect of IL4 on CD20 expression was associated with an induction of BCP maturation as judged by expression of IgM. According to these criteria, our results demonstrate that IL-4 does not permit to override the maturation block in BCP-ALL, in that it failed to promote the emergence of sIgM+ cells (and of cg' cells in the cases of cg-leukemia). In this context, little data is available on the effects of cytokines on the differentiation of leukemic BCP. Wormann et al. (35) have described a human pre-B ALL cell line which spontaneously acquired sIgM through cloning selection, but not through exposure to a number of cytokines, including IL-4.
A number of studies have reported cytokine-mediated induction of Ig expression in normal murine and human BCP. In this context, we found that IL-4 did not enhance the spontaneous emergence of sIgM+ cells from CDI0+ sIgMcells, in accordance with Le Bien ( 16) . Furthermore, IL-4 failed to affect the numbers of cqg (pre-B) cells present in our cultures.
In contrast to these data, Hofman et al. ( 15) have reported that IL-4 favors the transition to cu+ and sIgM+ cells in cultures of human CD24+ fetal cells, in accordance with several studies on murine BCP (12) (13) (14) . It has been suggested, however, that the effects of IL-4 on murine BCP are indirectly mediated through accessory cells (9), or reflect enhanced survival of sIgM+ cells in the presence of IL-4 (36) . In this respect, the CD24+ cell population used in the study by Hofman et al. ( 15 ) initially contains a significant proportion of sIgM' cells, and thus cannot be directly compared to the CDI0O sIgMpopulation presently analyzed. Although IL-4 failed to increase the numbers of sIgM' cells in our cultures of CDI0 sIgMfetal cells, it induced hyperexpression of sIgM. This effect is likely to be related to IL-4 induced hyperexpression of sIgM on sIgM+ cells (37, 38) .
Taken together, our results demonstrate that IL4, by itself, does not drive the transition from BCP to fully mature B cells. Nevertheless, this conclusion does not rule out the possibility of an in vivo regulatory role for IL-4 in BCP maturation. In such a scheme, IL-4 derived from bone marrow stromal cells ( 13) could interact with accessory cells, and/or directly in association with another cytokine, to promote BCP maturation. Such a model would be compatible with our present demonstration that IL-4 can inhibit proliferation at some stages of BCP development. However, further studies will be required to address the precise role of IL-4 in human B cell ontogeny.
